CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Public ClinicalTrials.gov record NCT04660929. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
Study identification
- NCT ID
- NCT04660929
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 48 participants
Conditions and interventions
Conditions
- HER2-positive
- Adenocarcinoma
- Bile Duct Cancer
- Biliary Tract Cancer
- Bladder Cancer
- Breast Cancer
- Breast Neoplasm
- Carcinoma, Ductal
- Carcinoma, Hepatocellular
- Cancer
- Lung Cancer, Non-Small-Cell
- Carcinoma, Ovarian Epithelial
- Carcinoma, Small Cell
- Carcinoma, Squamous
- Carcinoma, Transitional Cell
- Colorectal Cancer
- Esophagogastric Junction Neoplasms
- Inflammatory Breast Cancer
- Stomach Neoplasms
- Malignant Neoplasms
- Ovarian Neoplasms
- Pancreatic Cancer
- HER2-positive Solid Tumors
- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER-2 Protein Overexpression
- HER-2 Gene Amplification
- Prostate Cancer
- Head and Neck Cancer
- Endometrial Cancer
- Lung Cancer, Small Cell
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2021 (Actual)
- Primary completion
- Dec 31, 2024 (Estimated)
- Completion
- Dec 31, 2024 (Estimated)
- Last update posted
- Dec 18, 2024
2021 – 2024
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Tennessee Oncology / Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04660929, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04660929 live on ClinicalTrials.gov.